Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

273 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients.
Morales L, Timmerman D, Neven P, Konstantinovic ML, Carbonez A, Van Huffel S, Ameye L, Weltens C, Christiaens MR, Vergote I, Paridaens R. Morales L, et al. Among authors: paridaens r. Ann Oncol. 2005 Jan;16(1):70-4. doi: 10.1093/annonc/mdi021. Ann Oncol. 2005. PMID: 15598941 Free article. Clinical Trial.
Reply to the Letter to the Editor on "Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients", by I. Cohen Ann Oncol 2005; 16: 1399.
Paridaens R, Morales L, Neven P, Timmerman D. Paridaens R, et al. Ann Oncol. 2005 Aug;16(8):1402-3; author reply 1402-3. doi: 10.1093/annonc/mdi237. Epub 2005 May 3. Ann Oncol. 2005. PMID: 15870087 Free article. No abstract available.
Adjuvant therapy for postmenopausal ER-positive breast cancer. Why tamoxifen still has a future? The Leuven point of view.
Neven P, Paridaens R, Amant F, Wildiers H, Berteloot P, Leunen K, Smeets A, Weltens C, van den Bogaert W, van Limbergen E, Christiaens MR, Vergote I. Neven P, et al. Among authors: paridaens r. Int J Gynecol Cancer. 2006;16 Suppl 2:505-10. doi: 10.1111/j.1525-1438.2006.00682.x. Int J Gynecol Cancer. 2006. PMID: 17010059 Review. No abstract available.
Prevalent breast cancer patients with a homozygous mutant status for CYP2D6*4: response and biomarkers in tamoxifen users.
Dieudonné AS, Lambrechts D, Claes B, Vandorpe T, Wildiers H, Timmerman D, Billen J, Leunen K, Amant F, Berteloot P, Smeets A, Paridaens R, Weltens C, Van Limbergen E, Van den Bogaert W, Vergote I, Van Huffel S, Christiaens MR, Neven P. Dieudonné AS, et al. Among authors: paridaens r. Breast Cancer Res Treat. 2009 Dec;118(3):531-8. doi: 10.1007/s10549-009-0463-5. Epub 2009 Jul 12. Breast Cancer Res Treat. 2009. PMID: 19597703
Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis.
Lintermans A, Van Calster B, Van Hoydonck M, Pans S, Verhaeghe J, Westhovens R, Henry NL, Wildiers H, Paridaens R, Dieudonné AS, Leunen K, Morales L, Verschueren K, Timmerman D, De Smet L, Vergote I, Christiaens MR, Neven P. Lintermans A, et al. Among authors: paridaens r. Ann Oncol. 2011 Aug;22(8):1763-9. doi: 10.1093/annonc/mdq699. Epub 2011 Jan 27. Ann Oncol. 2011. PMID: 21273342 Free article.
Prospective study to assess fluid accumulation and tenosynovial changes in the aromatase inhibitor-induced musculoskeletal syndrome: 2-year follow-up data.
Lintermans A, Laenen A, Van Calster B, Van Hoydonck M, Pans S, Verhaeghe J, Westhovens R, Henry NL, Wildiers H, Paridaens R, Dieudonné AS, Leunen K, Morales L, Verschueren K, Timmerman D, De Smet L, Vergote I, Christiaens MR, Neven P. Lintermans A, et al. Among authors: paridaens r. Ann Oncol. 2013 Feb;24(2):350-355. doi: 10.1093/annonc/mds290. Epub 2012 Oct 4. Ann Oncol. 2013. PMID: 23038762 Free article.
A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI.
Lintermans A, Van Asten K, Wildiers H, Laenen A, Paridaens R, Weltens C, Verhaeghe J, Vanderschueren D, Smeets A, Van Limbergen E, Leunen K, Christiaens MR, Neven P. Lintermans A, et al. Among authors: paridaens r. Breast Cancer Res Treat. 2014 Jul;146(1):109-16. doi: 10.1007/s10549-014-2986-7. Epub 2014 May 11. Breast Cancer Res Treat. 2014. PMID: 24816806
Body mass index and HER-2 overexpression in breast cancer patients over 50 years of age.
Van Mieghem T, Leunen K, Pochet N, De Moor B, De Smet F, Amant F, Berteloot P, Timmerman D, Vanden Bempt I, Drijkoningen R, Wildiers H, Paridaens R, Smeets A, Hendrickx W, Van Limbergen E, Christiaens MR, Vergote I, Neven P. Van Mieghem T, et al. Among authors: paridaens r. Breast Cancer Res Treat. 2007 Nov;106(1):127-33. doi: 10.1007/s10549-006-9474-7. Epub 2007 Jan 9. Breast Cancer Res Treat. 2007. PMID: 17211534
273 results